Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses the HMI-115 trial for hair loss, which was expected to end around July 2023 due to a late participant. Participants also mention Minoxidil, finasteride, and RU58841 as treatments.

Pyrilutamide, a hair loss treatment, is undergoing clinical trials in China and may be available in a few years. Users discuss the possibility of obtaining it early through group buys and synthesis by labs.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

The conversation discusses severe hair loss, possibly due to telogen effluvium or male pattern baldness, lasting over three years. Suggested treatments include minoxidil, finasteride, and dermarolling, with a recommendation to consult a dermatologist.

The user experienced significant hairline improvement after 2 months using 1 mg Finasteride and topical Minoxidil, with only initial shedding as a side effect. The progress is notable, with the user returning from near Norwood 2 to Norwood 1, and they use Rogaine for topical application.

Stopping Minoxidil leads to hair reverting to its natural state, while stopping Finasteride may delay but not prevent eventual hair loss progression. Finasteride slows hair loss by reducing DHT damage, but once stopped, hair loss resumes, potentially at a slower rate.

The user experienced initial hair regrowth with 1 mg finasteride and 5 mg minoxidil but began shedding after 4-5 months, which others suggest is common and may lead to thicker regrowth. Users recommend patience, as results can take up to 12-24 months, and suggest considering specialized clinics for hairline design if unsatisfied with medication alone.

The user experienced significant hair regrowth after 2.5 years of using Minoxidil 5% and hormone replacement therapy (HRT) with Lupron, despite initial scalp irritation. Finasteride was ineffective for them.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

The user shared progress photos of hair regrowth using copper peptides and NAD+ over five months. Another user commented on the lighting, and another praised the progress.

The user experienced regrowth and stabilization in hair density using finasteride, minoxidil, a derma roller, and an LLLT helmet, but noticed a recent decline in hair quality. They only take finasteride orally and are unsure about the effectiveness of the LLLT device.

Finasteride is not linked to a 60% risk of persistent sexual dysfunction; this figure applies only to those already experiencing sexual issues. Most users do not have side effects, and the study's methodology is criticized for selection bias.

The conversation discusses using a low dose of finasteride (0.25-0.33mg) for hair loss maintenance, with some users suggesting alternatives like topical finasteride and addressing sleep issues potentially unrelated to the medication. Suggestions include taking finasteride in the morning, improving sleep hygiene, and considering melatonin.

The user experienced significant hair thickening after nearly 5 months on 5 mg oral minoxidil and over 10 years on 1 mg finasteride, with no side effects. They are considering a hair transplant for the hairline but are pleased with the current results.

RU58841 is discussed as a hair loss treatment, with concerns about its effectiveness diminishing after two years due to androgen receptor upregulation. The user is hesitant to start using it, fearing it may worsen their condition over time.

The user has been using topical minoxidil for over two years and finasteride 1mg for six and a half months, noticing some progress without side effects. They mention initial concerns about side effects but attribute difficulties to lack of sleep and long work hours.

People are pessimistic about PP405, believed to be Jxl-069, due to doubts about its effectiveness and delivery method. Some think it doesn't work, while others blame the vehicle used for application.

The conversation discusses the side effects of finasteride, including low libido and erectile dysfunction, and the possibility of these effects being permanent, known as post-finasteride syndrome (PFS). Some users report personal experiences with PFS and debate whether the condition is real, with varying opinions on the reversibility of side effects and the role of individual biology.

Dutasteride can take 6-12 months to show full effects, and initial hair shedding is normal. Users suggest continuing treatment consistently and checking progress around the 6-month mark.

The user experienced significant hair thickening after 9 months using 2.5mg oral minoxidil and 1mg finasteride daily, with minor side effects like increased body hair. They advise patience with finasteride, noting it can take up to a year to see results.

The user is using oral minoxidil for hair growth and is considering adding topical latanoprost, but is concerned about potential eye color change. They are seeking advice on the effectiveness of latanoprost for hair thickening and the risk of eye color change.

Breezula is expected to launch in late 2026, with data being sent to the FDA in early 2026. The process is typical for a successful trial.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

A user discusses using dermastamping for hair loss and questions the timing of applying a mixture of peppermint oil, spearmint oil, rosemary oil, and castor oil due to their anti-inflammatory effects. They wonder if waiting 10 hours after stamping would be more effective.

Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.

People using minoxidil and finasteride often see hair regrowth results around 4-5 months, but some experience no progress even after 10 months. Switching to dutasteride or adjusting dosages can lead to improvements, with some users noticing changes as early as 3 months.

Pelage Pharmaceuticals is starting Phase 3 trials for PP405 in September 2026, with potential market release by 2030. Users discuss various hair loss treatments like minoxidil, finasteride, RU58841, kx, breezula, and gt20029, expressing hope for future hair restoration.

User experienced side effects from topical finasteride, including penile pain and reduced sexual satisfaction, and is unsure whether to resume or avoid the treatment. They are seeking advice on whether tapering off the drug might help.